Drugs / Gelfoam
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03669003 | Dec 2018 → Dec 2019 | pneumothorax | University of Miami | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02338297 | Feb 2016 → Feb 2017 | hepatocellular carcinoma | Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gelfoam | “Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)” NCT02338297 ↗ |
| Route | Other | “The slurry is semisolid in consistency and can be easily injected through the biopsy cannula into the needle track.” NCT03669003 ↗ |